Veracyte (NASDAQ:VCYT) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Veracyte (NASDAQ:VCYT) issued its earnings results on Thursday. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.11, FiscalAI reports. The company had revenue of $150.32 million during the quarter, compared to analyst estimates of $144.59 million. Veracyte had a return on equity of 9.07% and a net margin of 16.25%.The firm’s quarterly revenue was up 15.5% on a year-over-year basis. During the same quarter last year, the business posted $0.44 EPS.

Here are the key takeaways from Veracyte’s conference call:

• Strong Q2 results: Revenue rose 15% year over year to $150.3 million, testing volume increased 13% to approximately 51,000 tests, and adjusted EBITDA grew 23% to $44 million, or 29.2% of revenue. The company generated $45.8 million in operating cash flow and ended the quarter with $485.2 million in cash and short-term investments.
• Veracyte raised its 2026 revenue outlook to $590 million-$596 million, reflecting 14%-15% growth, while maintaining adjusted EBITDA guidance above 26%. The outlook assumes approximately 20% Decipher revenue growth and excludes contributions from the recently launched Prosigna LDT and TrueMRD products.
• The company launched Prosigna LDT for ER-positive, HER2-negative breast cancer and TrueMRD for recurrence monitoring in muscle-invasive bladder cancer. Early physician and patient response has been encouraging, more than 100 institutions are engaged on Prosigna, and Veracyte is expanding its sales force and investing in electronic health-record integration.
• Decipher Prostate volume expectations were reduced by approximately 1,000 tests for 2026, primarily because low-risk testing is growing only at a single-digit rate after an NCCN guideline change removed genomic testing from active-surveillance recommendations. Management expects additional clinical studies, with initial readouts beginning as early as 2027, to support potential future adoption.
• Afirma continued to gain traction, with volume up 10% and revenue up 18% year over year to approximately 18,600 tests. Higher reimbursement, pricing improvements, market-share gains, and the V2 transcriptome workflow’s lower no-result rate supported growth and improved testing gross margins.

Veracyte Stock Performance

Shares of Veracyte stock traded down $14.54 during trading hours on Friday, reaching $45.24. 825,647 shares of the company were exchanged, compared to its average volume of 1,028,169. The firm has a market cap of $3.61 billion, a PE ratio of 41.88 and a beta of 1.93. Veracyte has a 1 year low of $22.92 and a 1 year high of $60.91. The stock’s fifty day moving average is $53.69 and its 200 day moving average is $42.29.

Insider Activity

In other Veracyte news, CEO Marc Stapley sold 138,051 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $50.12, for a total transaction of $6,919,116.12. Following the sale, the chief executive officer owned 440,494 shares in the company, valued at $22,077,559.28. This represents a 23.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Robert S. Epstein sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $44.01, for a total transaction of $440,100.00. Following the transaction, the director owned 52,446 shares of the company’s stock, valued at $2,308,148.46. This trade represents a 16.01% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 206,696 shares of company stock worth $10,079,058 over the last three months. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in VCYT. Xponance LLC lifted its position in shares of Veracyte by 12.1% during the 4th quarter. Xponance LLC now owns 6,871 shares of the biotechnology company’s stock worth $289,000 after buying an additional 741 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new position in shares of Veracyte in the 3rd quarter valued at $287,000. Oxford Asset Management LLP purchased a new position in shares of Veracyte in the 2nd quarter valued at $285,000. CIBC Private Wealth Group LLC lifted its position in Veracyte by 599.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 6,195 shares of the biotechnology company’s stock valued at $261,000 after acquiring an additional 5,309 shares during the last quarter. Finally, Systematic Alpha Investments LLC acquired a new stake in shares of Veracyte during the fourth quarter worth about $240,000.

Analyst Ratings Changes

A number of brokerages have recently commented on VCYT. UBS Group upped their target price on Veracyte from $48.00 to $52.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Needham & Company LLC boosted their price target on shares of Veracyte from $57.00 to $69.00 and gave the stock a “buy” rating in a report on Friday. Zacks Research lowered Veracyte from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Weiss Ratings restated a “hold (c)” rating on shares of Veracyte in a report on Wednesday, June 24th. Finally, Wall Street Zen raised shares of Veracyte from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Veracyte has an average rating of “Moderate Buy” and a consensus price target of $57.38.

Key Headlines Impacting Veracyte

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Veracyte reported second-quarter adjusted earnings of $0.54 per share, well above the analyst consensus of $0.43 and up from $0.44 a year earlier. Revenue rose 15.5% year over year to $150.3 million, exceeding expectations of approximately $144.6 million. Veracyte Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Core testing revenue increased 19% to $145.7 million, outpacing total company growth and highlighting continued demand for Veracyte’s genomic diagnostic tests. Veracyte Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised its fiscal 2026 revenue guidance to $590 million-$596 million, above the prior outlook and the roughly $585 million analyst consensus. The higher forecast suggests management expects sustained volume and commercial momentum through the remainder of the year. Veracyte Q2 Non-GAAP Earnings, Revenue Rise; 2026 Revenue Guidance Raised
• Neutral Sentiment: Despite the strong results, commentary questioning whether Veracyte is “fully valued” could temper enthusiasm. With the stock’s elevated earnings multiple and shares already trading near the upper portion of their long-term range, investors may demand continued earnings upgrades to support additional gains. Is Veracyte Fully Valued After Raising 2026 Revenue Guidance?

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.